[go: up one dir, main page]

NO20076119L - Diagnostisk markor for diabetiske vaskulaere komplikasjoner - Google Patents

Diagnostisk markor for diabetiske vaskulaere komplikasjoner

Info

Publication number
NO20076119L
NO20076119L NO20076119A NO20076119A NO20076119L NO 20076119 L NO20076119 L NO 20076119L NO 20076119 A NO20076119 A NO 20076119A NO 20076119 A NO20076119 A NO 20076119A NO 20076119 L NO20076119 L NO 20076119L
Authority
NO
Norway
Prior art keywords
diagnostic marker
vascular complications
diabetic vascular
diabetic
complications
Prior art date
Application number
NO20076119A
Other languages
English (en)
Inventor
William R Usinger
Ayad A Jaffa
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of NO20076119L publication Critical patent/NO20076119L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

Foreliggende oppfinnelse gjelder den oppdagelse at CTGF er en diagnostisk markør som indikerer forhøyet risiko for utvikling og progresjon av karsykdom.
NO20076119A 2005-05-05 2007-11-27 Diagnostisk markor for diabetiske vaskulaere komplikasjoner NO20076119L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67825105P 2005-05-05 2005-05-05
PCT/US2006/017755 WO2006122043A2 (en) 2005-05-05 2006-05-05 Diagnostic marker for diabetic vascular complications

Publications (1)

Publication Number Publication Date
NO20076119L true NO20076119L (no) 2008-01-30

Family

ID=37343788

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076119A NO20076119L (no) 2005-05-05 2007-11-27 Diagnostisk markor for diabetiske vaskulaere komplikasjoner

Country Status (11)

Country Link
US (1) US20090325302A1 (no)
EP (1) EP1889072A2 (no)
JP (1) JP2008541062A (no)
CN (1) CN101213456A (no)
AU (1) AU2006244144A1 (no)
CA (1) CA2606812A1 (no)
IL (1) IL187114A0 (no)
MX (1) MX2007013831A (no)
NO (1) NO20076119L (no)
WO (1) WO2006122043A2 (no)
ZA (1) ZA200710199B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009141357A1 (en) * 2008-05-20 2009-11-26 Roche Diagnostics Gmbh Gdf-15 as biomarker in type 1 diabetes
KR101249041B1 (ko) 2010-04-28 2013-03-29 포항공과대학교 산학협력단 결합조직 성장인자를 이용한 약학적 조성물
EP3151012B1 (en) * 2010-09-21 2018-03-21 Proteomics International Pty Ltd Biomarkers associated with diabetic nephropathy
JP6128631B2 (ja) * 2012-08-01 2017-05-17 国立大学法人名古屋大学 糖尿病性腎症鑑別用マーカー及びその用途
CN106906278A (zh) * 2015-12-22 2017-06-30 复旦大学 预测ii型糖尿病心血管并发症风险的生物标记物及其用途
CN109411062A (zh) * 2018-09-30 2019-03-01 天津科技大学 一种基于深度学习技术利用生理参数自动判断糖尿病及其并发症的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE485834T1 (de) * 1998-09-08 2010-11-15 Ford Henry Health System Verfahren zum nachweis von bindegewebswachstumsfaktor zur diagnose von nierkrankheiten
AU2002326939A1 (en) * 2001-09-18 2003-04-01 Fibrogen, Inc. Methods of assaying connective tissue growth factor
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes

Also Published As

Publication number Publication date
JP2008541062A (ja) 2008-11-20
MX2007013831A (es) 2008-02-05
CA2606812A1 (en) 2006-11-16
IL187114A0 (en) 2008-02-09
EP1889072A2 (en) 2008-02-20
US20090325302A1 (en) 2009-12-31
ZA200710199B (en) 2009-06-24
WO2006122043A2 (en) 2006-11-16
AU2006244144A1 (en) 2006-11-16
WO2006122043A3 (en) 2007-03-29
CN101213456A (zh) 2008-07-02

Similar Documents

Publication Publication Date Title
ATE516746T1 (de) Vorrichtung für die kontinuierliche, nicht- invasive messung des arteriellen blutdrucks und ihre verwendung
NO20076119L (no) Diagnostisk markor for diabetiske vaskulaere komplikasjoner
EP1876236A4 (en) ANTIBODY AS A FUNCTIONAL REPLACEMENT FOR BLOOD CREATION FACTOR VIII
CY1112067T1 (el) Χρηση φλιμπανσερινης για την θεραπεια διαταραχων προ-εμμηνοπαυσιακης σεξουαλικης επιθυμιας
EA200802213A1 (ru) Способы лечения заболеваний крови
DE502004012226D1 (de) Saugstent
BRPI0610308A8 (pt) Composições e métodos para o tratamento de doença retinal
CL2008000594A1 (es) Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades.
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
NO20082904L (no) Feksofenadinsupensjonsformulering
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE602005002930D1 (de) Sulfonamidderivate zur behandlung von krankheiten
EP2293077A3 (en) Methods for detecting coronary artery disease
NO20076405L (no) Anvendelse av 24-nor-UDCA
EA200900261A1 (ru) Применение эсцина
ATE499344T1 (de) Peri-substituierte bicyclische sulfonamide gegen arterielle verschlusskrankheit
DE102005024352B8 (de) Medizinisches Instrument für endoskopische Eingriffe
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
ATE512144T1 (de) Peri-substituierte bicyclische arylsulfonamide gegen arterielle verschlusskrankheiten
EP1908786A4 (en) 2-cyanoacrylate
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
DE502005008610D1 (de) Spreizbares medizinisches Instrument für endoskopische Eingriffe
DK1251875T3 (da) Anvendelse af kontrastmidler til fremstilling af et diagnostisk middel til visualisering af intestinallumen
EA200801425A1 (ru) Диазепиноны
ATE475424T1 (de) Cellulosesulfat zur behandlung von rhinovirus- infektionen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application